University of Nebraska Medical Center

DigitalCommons@UNMC
Journal Articles: Biochemistry & Molecular
Biology

Biochemistry & Molecular Biology

8-6-2007

Human MUC4 mucin induces ultra-structural changes and
tumorigenicity in pancreatic cancer cells.
N. Moniaux
University of Nebraska Medical Center

P. Chaturvedi
University of Nebraska Medical Center

G. C. Varshney
Institute of Microbial Technology

Jane L. Meza
University of Nebraska Medical Center, jmeza@unmc.edu

J. F. Rodriguez-Sierra
University of Nebraska Medical Center, jrodrigu@unmc.edu

See next page for additional authors
Follow this and additional works at: https://digitalcommons.unmc.edu/com_bio_articles
Part of the Medical Biochemistry Commons, and the Medical Molecular Biology Commons

Recommended Citation
Moniaux, N.; Chaturvedi, P.; Varshney, G. C.; Meza, Jane L.; Rodriguez-Sierra, J. F.; Aubert, J-P; and Batra,
Surinder K., "Human MUC4 mucin induces ultra-structural changes and tumorigenicity in pancreatic
cancer cells." (2007). Journal Articles: Biochemistry & Molecular Biology. 98.
https://digitalcommons.unmc.edu/com_bio_articles/98

This Article is brought to you for free and open access by the Biochemistry & Molecular Biology at
DigitalCommons@UNMC. It has been accepted for inclusion in Journal Articles: Biochemistry & Molecular Biology
by an authorized administrator of DigitalCommons@UNMC. For more information, please contact
digitalcommons@unmc.edu.

Authors
N. Moniaux, P. Chaturvedi, G. C. Varshney, Jane L. Meza, J. F. Rodriguez-Sierra, J-P Aubert, and Surinder K.
Batra

This article is available at DigitalCommons@UNMC: https://digitalcommons.unmc.edu/com_bio_articles/98

British Journal of Cancer (2007) 97, 345 – 357
& 2007 Cancer Research UK All rights reserved 0007 – 0920/07 $30.00

www.bjcancer.com

Human MUC4 mucin induces ultra-structural changes and
tumorigenicity in pancreatic cancer cells
N Moniaux1,6, P Chaturvedi1,6, GC Varshney2, JL Meza3, JF Rodriguez-Sierra4, J-P Aubert5 and SK Batra*,1

MUC4 is a type-1 transmembrane glycoprotein and is overexpressed in many carcinomas. It is a heterodimeric protein of 930 kDa,
composed of a mucin-type subunit, MUC4a, and a membrane-bound growth factor-like subunit, MUC4b. MUC4 mRNA contains
unique 50 and 30 coding sequences along with a large variable number of tandem repeat (VNTR) domain of 7 – 19 kb. A direct
association of MUC4 overexpression has been established with the degree of invasiveness and poor prognosis of pancreatic cancer.
To understand the precise role of MUC4 in pancreatic cancer, we engineered a MUC4 complementary DNA construct, mini-MUC4,
whose deduced protein (320 kDa) is comparable with that of wild-type MUC4 (930 kDa) but represents only 10% of VNTR. Stable
ectopic expression of mini-MUC4 in two human pancreatic cancer cell lines, Panc1 and MiaPaCa, showed that MUC4 minigene
expression follows a biosynthesis and localisation pattern similar to the wild-type MUC4. Expression of MUC4 resulted in increased
growth, motility, and invasiveness of the pancreatic cancer cells in vitro. Ultra-structural examination of MUC4-transfected cells
showed the presence of increased number and size of mitochondria. The MUC4-expressing cells also demonstrated an enhanced
tumorigenicity in an orthotopic xenograft nude mice model, further supporting a direct role of MUC4 in inducing the cancer
properties. In conclusion, our results suggest that MUC4 promotes tumorigenicity and is directly involved in growth and survival of
the cancer cells.
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MUC4 is a high molecular weight O-glycoprotein produced by
secretory epithelial cells for the lubrication and protection of ducts
and lumen (Porchet et al, 1991; Khorrami et al, 2002). MUC4 is
expressed in various epithelial tissues including the trachea, colon,
stomach, cervix, and lung (Audie et al, 1993, 1995). It is also
expressed in goblet, ciliated, and absorptive cells in adults and in
poorly differentiated cells of embryos and fetuses (Buisine et al,
1998, 1999). Indeed, MUC4 is expressed early in the primitive gut,
before respiratory and digestive epithelial cells have acquired their
tissue and cell specificity. For these reasons, morphogenic
differentiation and embryonic development functions are attributed to MUC4, and its expression can be regulated by several
serum factors including retinoids (Ogata et al, 1992; Choudhury
et al, 2000b), growth factors, and cytokines (Andrianifahanana
et al, 2005).
The largest size of MUC4 allele is approximately 26.5 kb. Its
deduced amino-acid sequence consists of a 27-residue peptide
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signal sequence followed by three imperfect repetitions of a motif
varying in size from 126 to 130 residues and a unique sequence of
554 residues. The central domain is composed of a perfect
repetition motif of 16 amino-acid residues, which is repeated 400
times in the largest allele. The C-terminal region contains two
domains rich in N-glycosylation sites, three epidermal growth
factor-like domains, a transmembrane sequence, and a short
cytoplasmic tail. The MUC4 protein is hypothesised to be
proteolytically cleaved at a GDPH site generating two subunits,
the mucin-type subunit, MUC4a, and the growth factor-like
subunit, MUC4b. MUC4 is predicted to be a membrane-associated
2.12 mm long, mature protein where both subunits stay noncovalently bound.
The genomic organisation of MUC4 is fully understood, and its
characterisation has been substantially aided by the human
genome project (DOE Joint Genome Institute Human Genome
Project). MUC4 encompasses 25 exons, the first exon, E1, encoding
the 50 -untranslated sequence, the translation start site, and the
peptide signal (Escande et al, 2002). Exons range from 65 bp to
22 kb in size, whereas introns range from 94 bp to 16.5 kb. The
largest exon, E2, is at the central position and contains a large
2.8 kb unique sequence followed by the repetition of a 48 bp motif.
The tandem repeat region in E2 shows a variable number of
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MATERIALS AND METHODS
Generation of mini-MUC4 gene
The construction of the MUC4 minigene was performed in three
steps (Figure 1A). First, the unique sequences of MUC4 were
amplified by PCR: two fragments for the 50 -unique sequence, a
British Journal of Cancer (2007) 97(3), 345 – 357
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tandem repeat (VNTR) polymorphism, and its size varies from 7.5
to 19 kb. The largest known allele for MUC4 expresses a 26.5 kb
transcript that encodes the full-length MUC4 precursor, also called
sv0-MUC4.
MUC4 is highly expressed in human pancreatic tumours and
pancreatic tumour cell lines; however, its expression is undetectable in the normal pancreas or chronic pancreatitis (Balague et al,
1994; Hollingsworth et al, 1994; Choudhury et al, 2000a;
Andrianifahanana et al, 2001). MUC4 is expressed by metaplastic
ducts and its expression increases with increasing grade in
pancreatic intraepithelial neoplasias (Swart et al, 2002; Park
et al, 2003). A recent study has shown that MUC4 is a good
candidate marker for early diagnosis of pancreatic cancer in fineneedle aspirates, exhibiting a 91% sensitivity and 100% specificity
(Jhala et al, 2006). MUC4 expression in a variety of cancer is
associated with poor prognosis (Bax et al, 2004; Weed et al, 2004;
Alos et al, 2005; Handra-Luca et al, 2005; Jhala et al, 2006). The
inhibition of MUC4 expression by an antisense oligonucleotide
resulted in decreased in vivo tumorigenicity and metastasis (Singh
et al, 2004). Altogether, these data establish a strong association
between MUC4 expression and pancreatic cancer pathogenesis.
Moreover, in the rat model, sialomucin complex (SMC)/rMuc4,
represses cell adhesion, blocks tumour cell killing, promotes the
growth of the tumour, and is directly related to the metastatic
invasion (Carraway et al, 2000). However, our understanding
about the role of MUC4 in the development and progression of
pancreatic adenocarcinoma is still unclear.
One of the hallmarks in cancer development is the inhibition of
apoptosis with a central role of the mitochondria in this process.
During carcinogenesis mitochondria present an enhanced aerobic
glycolysis as a protective mechanism against reactive oxygen
species, an acidification of the microenvironment that favours cell
invasion and an enhanced resistance to mitochondria-induced
apoptosis (Brand and Hermfisse, 1997; Kroemer, 2006). In addition
to their role in apoptosis, mitochondria play a pivotal role in
cellular metabolism, respiration, and production of ATP essential
for the normal function of all human organ systems. Therefore, the
mitochondrial content for any given cell is well regulated,
presenting variation with the type of the cells and tissues, during
cell differentiation, hormone treatment, and exercise (Robin and
Wong, 1988; Renis et al, 1989; Shay et al, 1990). Increase in
mitochondrial mass is directly associated with cell division and cell
differentiation. In cancer cells, other roles have also been linked to
increase in mitochondrial mass, including increased resistance to
tamoxifen-induced apoptosis in breast cancer, further suggesting
role of mitochondria in cancer progression (Dietze et al, 2001).
To elucidate further the functions of human MUC4, a
recombinant MUC4 minigene was generated and stably transfected
in pancreatic adenocarcinoma cell lines Panc1 and MiaPaCa. The
mini-MUC4 was surface-localised in both the transfected cell lines.
Expression of mini-MUC4 increased in vitro growth, motility, and
invasiveness of the pancreatic cancer cells. Ultra-structural studies
showed increased mitochondrial size in mini-MUC4-transfected
cells, which was correlative with increased mitochondrial mass.
Furthermore, overexpression of the mini-MUC4 gene in pancreatic
cancer cells also resulted in an increase in tumorigenicity of these
cells in vivo. Our results demonstrate, for the first time, a direct
role of the MUC4 mucin with the cellular changes and tumour
progression in human pancreatic cancer cells.

GDPH
(TR 10% of WT)

Mini-MUC4
3009 bp
MUC4!

3491 bp
MUC4"

Figure 1 Construction of the mini-MUC4. (A) Schematic representation
of cloning strategy for the generation of the mini-MUC4 construct.
Fragments amplified by PCR were subcloned in PCR2.1 vector, sequenced,
digested with specific restriction sites, and subcloned in the pBluescript
vector. Finally, the 50 region, JER64 fragment, and the 30 fragments were
subcloned in the pSecTag C vector. Each junction was sequenced to
confirm the reading frame. (B) A schematic representation of mini-MUC4
gene. The sequence of the mini-MUC4 (320 kDa) is comparable with that
of wild-type MUC4 (930 kDa), but with a repetitive domain representing
only 10% the normal size.

SalI/EcoRI product from position – 71 to 178, and an EcoRI/BamHI
product from 179 to 2919 (AJ000281). Two fragments were
amplified by PCR for the 30 -unique sequence, an EcoRV/HindIII
product from position 1 to 1351 and a HindIII/NotI product from
position 1352 to 3471 (AJ010901). Each product was cloned into
pCR2.1 (Invitrogen, Carlsbad, CA, USA). Both 50 and 30 fragments
were extracted by the introduced restriction endonuclease sites
and subcloned into the pBluescript KS( þ ) vector (Stratagene, La
Jolla, CA, USA) to get a SalI/BamHI 50 -full sequence and a EcoRV/
NotI 30 -full sequence. In a second step, a new HindIII/BamHI PCR
product was performed using the 50 -full sequence as a template,
and cloned into the pCR2.1 vector. This fragment is located from
position 100 to 2919 (AJ00281). The EcoRI complementary DNA
(cDNA) fragment named JER64 coding the repetitive sequence of
MUC4 was extracted and subcloned into the pSecTag C vector.
Finally, the HindIII/BamHI 50 fragment, as well as the EcoRV/NotI
30 -full sequence, were extracted and subcloned in frame into the
pSecTag C containing the sequence repeated in tandem. At each
& 2007 Cancer Research UK
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Expression of mini-MUC4 cDNA construct
Panc1 and MiaPaCa pancreatic adenocarcinoma cell lines were
transfected with plasmid DNA using the Lipofectamine method
(Invitrogen). Single colonies were obtained by zeocin selection and
expanded for screening. Cell lines were analysed for MUC4 protein
expression by western blot with a MUC4 peptide mouse
monoclonal antibody (8G7). Growth kinetic and population
doubling time of transfected and control cells were determined
as published previously (Singh et al, 2004).

Preparation of cell lysates and immunoblotting
Cell lysates were prepared in the lysis buffer (50 mM Tris – HCl (pH
7.4), 150 mM NaCl, 1% Nonidet P-40, 0.25% Na-deoxycholate, 1 mM
EDTA, 1 mM phenylmethylsulfonyl fluoride, 1mg/ml of aprotinin
and leupeptin, 1 mM Na3VO4, and 1 mM NaF). The protein content
of the lysates was determined by using the Bio-Rad DC protein
assay (Bio-Rad, Hercules, CA, USA). Cell lysates were resolved on a
2% sodium dodecyl sulphate (SDS)-agarose gel, transferred to
polyvinylidene difluoride (PVDF) membrane, and blocked in 5%
non-fat milk in phosphate-buffered saline (PBS) for 1 h. The MUC4
antibody was diluted at 1 mg/ml in PBS. The membrane was
incubated for 4 h at room temperature, followed by 6  10 min
washes in TBST (50 mM Tris – HCl (pH 7.4), 150 mM NaCl, and
0.05% Tween-20). The horseradish peroxidase (HRP)-conjugated
secondary antibody was diluted at 1 : 2000 in PBS, and the
membrane was incubated for 1 h at room temperature, followed
by six washes in TBST. Enhanced chemiluminescence reagents
were applied as per the manufacturer’s instructions (Amersham
Life Science, Piscataway, NJ, USA), and the blot was exposed to
ECL-sensitive film (Kodak, Rochester, NY, USA).

Confocal analysis
The cells were grown at 60 – 70% confluency on the sterilised
coverslip. Cells were first washed with 0.1 M HEPES containing
Hanks buffer and fixed in ice-cold methanol at ÿ201C for 2 min.
Methanol-fixed cells were blocked in 10% goat serum containing
0.05% Tween-20 for 30 min at room temperature before incubation
with primary antibody diluted (1 : 100) in 10% goat serum
containing PBS for 60 min at room temperature. Cells were washed
four times for 5 min with PBS containing 0.05% Tween-20 (PBST)
and then incubated with fluorescein isothiocyanate (FITC)conjugated goat anti-mouse secondary antibodies (Jackson
Immuno Research laboratories Inc., West Grove, PA, USA) for
60 min at room temperature. Cells were again washed with PBST,
five times for 5 min and mounted on a glass slide in the anti-fade
VECTASHIELD mounting media (Vector Laboratories Inc.,
Burlingame, CA, USA). Immunostaining was observed under the
Zeiss 510 LASER SCAN confocal microscope.

pore size 8 mm; Becton Dickinson, Franklin Lakes, NJ, USA). The
cells were incubated for 24 h, and the cells that did not migrate
through the pores in the membrane were removed by scraping the
membrane with a cotton swab. Cells that transversed the
membranes were stained with a Diff-Quick cell staining kit (Dade
Behring Inc., Newark, DE, USA). Cells in 10 random fields of view
at  100 magnification were counted and expressed as the average
number of cells per field of view. Three independent experiments
were performed in each case. The data were represented as the
average of the three independent experiments with the s.d. of the
average indicated.

Cell invasion assay
For Matrigel assay 1  105 cells were seeded on Matrigel-coated
membrane inserts. The bottom chamber contained 0.75 ml of
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum (FBS). After incubation for 24 h at 371C,
the cells remaining inside the insert were removed with a cotton
swab, and cells that penetrated the Matrigel and invaded to the
lower surface of the membrane were fixed in methanol and stained
using a Diff-quick reagent kit. After air-drying the membrane, the
cells were visually counted at a magnification of  100 under a
microscope. Assays were performed two times in triplicate wells,
and the cells present in 10 fields covering the centre of each
membrane were counted. Data were expressed as the number of
cells per area and as invasion index.

Electron microscopy
Cells cultured at 70% confluence, were washed twice in ice-cold
PBS, trypsinised, and fixed with 2.5% glutaraldehyde in 1 M
Sorenson’s phosphate buffer. The cell pellet was then subjected
to overnight infiltration in Dureapam Acm. Epoxy Resin (Electron
Microscopy Sciences, Fort Washington, PA, USA), flat embedding,
and polymerisation at 551C for 48 h. Embedded cells were mounted
on resin stubs and sectioned at 90 nm with an Ultracut E
ultramicrotome. Sections were viewed and photographed with a
Zeiss 600 EM10A transmission electron microscope (TEM) at
60 kV.

Determination of mitochondrial mass
The fluorescent dye 10-n-nonyl-acridine orange (NAO) (Molecular
Probes, Carlsbad, CA, USA) was used to monitor the mitochondrial mass. Cells were trypsinised and resuspended in 0.5 ml of
DMEM medium containing 5 mM of NAO, incubated for 30 min at
371C in the dark. After incubation, cells were kept on ice and
immediately analysed by flow cytometry. A FACScan flow
cytometer, equipped with a 488 nm argon laser, was used for the
flow-cytometric analysis. The forward and side scatters were used
to establish the size gates and to exclude cellular debris. The
excitation wavelength was at 488 nm and observation at 530 nm for
the green fluorescence and 585 nm for the red fluorescence.

Tumorigenicity assay
Apoptosis assay
Apoptosis was measured by using the Annexin V-FITC apoptosis
detection kit (Roche Diagnostics, Indianapolis, IN, USA). The cells
were grown in serum-free medium and the apoptosis was detected
by staining the cells with annexin V and propidium iodide
solution, followed by flow cytometry.

Cell motility assay
For motility assays, 1  106 cells were plated in the top chamber of
non-coated polyethylene teraphthalate membranes (six-well insert,
& 2007 Cancer Research UK

To test the tumorigenic capacity, mini-MUC4-transfected cells,
along with the control cells (parental and mock), were harvested
from subconfluent cultures, and resuspended in a normal saline
solution at a concentration of 4  107 cells/ml. Single-cell
suspensions of 490% viability were used for the injections.
Immunodeficient mice were purchased from the Animal Production Area of the National Cancer Institute/Frederick Cancer
Research and Development Center (Frederick, MD, USA). The
mice were housed in specific pathogen-free conditions and were
fed sterile water and food ad libitum. The mice were treated in
accordance with the Institutional Animal Care and Use Committee
British Journal of Cancer (2007) 97(3), 345 – 357
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guidelines. The mice (8- to 12-week old) were anaesthetised with
350 ml of intraperitoneal injection of a mixture (4 : 1) of ketamine
(100 mg/ml) and xylazine (20 mg/ml) diluted 10 times in sterile
water. A small left abdominal flank incision was made, and the
spleen was exteriorised. Tumour cells (2  106) were injected
subcapsularly in a region of the pancreas just beneath the spleen
using a 1-cc U-100 insulin disposable syringe (Becton Dickinson).
A successful subcapsular intrapancreatic injection of tumour cells
was identified by the appearance of a fluid bleb without
intraperitoneal leakage. To prevent leakage, a cotton swab was
held for 30 – 60 s over the site of injection. Wounds were closed by
making a single suture on one layer and three to five independent
sutures on the outermost skin. Tumour growth was assessed by
daily weighing and palpation of each animal. All mice were killed
on day 60 after implantation, and the presence of metastatic
lesions in different organs was determined. Pancreatic tumours
were excised, weighed, and measured for their dimensions.

Microarray analysis

Translational Therapeutics

RNA (60 mg) from MUC4-transfected cell lines and control mock
cell line were fluorescently labelled with Cy3- and Cy5-conjugated
dCTP (Amersham Pharmacia, Piscataway, NJ, USA), using
anchored oligo(dT) primers and Superscript II reverse transcriptase (Gibco-BRL, Gaithersburg, MD, USA). After probe generation,
residual RNA was hydrolysed by treatment with NaOH and
unincorporated nucleotides were removed by MicroCon YM-30
column (Amicon, Billerica, MA, USA). The latter step also serves to
concentrate the labelled cDNAs. Cy3- and Cy5-labelled cDNAs
were combined and diluted to 60 ml with 3.5  SSC/0.15% SDS
hybridisation solution. To reduce nonspecific hybridisation, the
hybridisation solution also contained 10 mg of poly (dA) (Pharmacia, St Louis, MD, USA), 2.5 mg of yeast transfer RNA (Sigma,
Ridgefield, CT, USA), and 12.5 mg of human Cot1 DNA (Boehringer-Mannheim, Ridgefield, CT, USA). The fluorescent probes were
denatured and hybridised to glass slides featuring approximately
6000 cDNA elements (University of Texas Southwestern Medical
Center Microarray Facility, Dallas, TX, USA) overnight at 651C.
Slides were washed successively in 1  SSC/0.1% SDS, 1  SSC,
and 0.2 SSC for 2 min each to remove excess probe and spun dried.
Hybridised arrays were scanned for fluorescent signals using
Scan Array 4000 confocal fluorescent laser scanner and accompanying ScanArray 3.0 software (Packard Instrument Company,
Meriden, CT, USA). For the MUC4-transfected vs mock cell line
plot, the log intensity in the Cy3-channel log2(Cy3-) and the log
intensity in the Cy5-channel log2(Cy5-) were transformed for
normalisation and visualisation purposes. A 451 counterclockwise
rotation of the (log2Cy3, log2Cy5)-coordinate system and a scaling
of the coordinates were applied to plot the log intensity ratio
M ¼ log2(Cy3/Cy5) vs the mean log intensity A ¼ log2ORCy3Cy5.
These two values were the features of interest for gene expression
microarray data. A print-tip-group lowess normalisation (Yang
et al, 2002) was applied to the plot. The lowess function is a
scatter-plot smoother that performs a robust local linear fit. The
printing setup of the arrayer implicated printing genes in 6  2
groups. Typically, systematic intensity-dependent differences
between such print-tip groups are observed. Separately, for every
print-tip group, a lowess normalisation was applied to the plot.
The normalisation was performed by subtracting the lowess fit
from the log intensity ratios M. This ensured that intensitydependent effects were removed from the data. All data
transformations were performed using the contributed R package
SMA (Statistical Microarray Analysis), available from ‘Terry
Speed’s Microarray Data Analysis Group Page’: http://www.stat.
berkeley.edu/users/terry/zarray/Html/index.html.
Calculated signal intensities and standard deviations for each
feature were background-corrected, normalised to total signal
intensities, and converted into ratios. The data were further
British Journal of Cancer (2007) 97(3), 345 – 357

analysed by imposing one or all of the following selection criteria:
(1) a minimum level of expression was observed; (2) significant
differential expression (twofold or greater) was observed; and (3)
the expression pattern was reproducible.

Statistical analysis
Statistical analyses were performed using SAS software (SAS
Institute, Cary, NC, USA). The Mann – Whitney U-test was used to
compare tumour weight and tumour volume between groups.
Fisher’s exact test was used to compare the frequency of metastasis
between groups. A P-value o0.05 was considered to be statistically
significant.

RESULTS
Construction of the mini-MUC4
The full-length coding sequence of MUC4 is difficult to subclone in
any known mammalian expression vector because of its dimensions and the repetitive nature of tandem repeat domain. To
overcome this problem, we used the first cDNA isolated for MUC4,
JER64 (Porchet et al, 1991), to design a mini-MUC4 construct. The
JER64 fragment contains a 1.8 kb long MUC4 tandem repeat
region, which is composed of the 48 bp motif in repetition. The
repetitive insert was subcloned in pSecTag C vector between the
EcoRI sites. The complete unique coding sequence and the 50 and
30 terminal sequences were then added in frame (Figure 1A)
(detailed in the Materials and Methods section). The 8781 bp miniMUC4 cDNA encoded an estimated 320 kDa protein, composed of
240 kDa mini-MUC4a subunit and the 80 kDa MUC4b subunit
(Figure 1B). The mini-MUC4 construct harbors all the unique
features of the wild-type MUC4, but contains only 10% of tandem
repeat region of the main allele (Nollet et al, 1998). Altogether, the
size of the mini-MUC4 represented 58% of the smallest and 30% of
the largest MUC4 wild-type alleles, and its size was comparable to
its rat homologue, SMC/rMuc4 (Carraway et al, 2000).

Expression and subcellular distribution of mini-MUC4
To evaluate the effects of mini-MUC4, multiple clones were
selected and characterised for the mini-MUC4 expression. MiniMUC4 was analysed by resolving the protein lysates isolated from
transfected cell lines (Panc1 and MiaPaCa) on a 2% SDS-agarose
horizontal gel followed by capillary transfer and immunoblotting
with anti-MUC4 antibody. The immunoblotting revealed a band
migrating at a distance consistent with the 320 kDa expected
molecular weight of mini-MUC4 (Figure 2A). The empty vectortransfected cells were negative for MUC4 expression. CD18/HPAF,
a MUC4 overexpressing cell line, was used as a positive control.
The subcellular localisation of mini-MUC4 and MUC4 wild type
was examined by indirect immunofluorescence and confocal laser
microscopy utilising the MUC4 monoclonal antibody. CD18/HPAF
cells showed both membraneous and cytoplasmic staining for
MUC4 (Figure 2B). A similar distribution of MUC4 was observed
for mini-MUC4-transfected Panc1 and MiaPaCa cells. Mini-MUC4
and wild-type MUC4 display a similar subcellular localisation,
indicating similar processing of MUC4 and mini-MUC4 in these
cells.

MUC4 enhances the in vitro growth of pancreatic cancer
cells
An overexpression of MUC4 mucin has been reported in a variety
of cancers. In addition, an inhibition of MUC4 mucin in pancreatic
cancer cells, using an antisense strategy, diminished in vitro and in
vivo growth of cancer cells. To study whether mini-MUC4 has the
similar effects on growth as wild-type MUC4, a growth kinetics
& 2007 Cancer Research UK
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Figure 2 Expression and subcellular localisation of mini-MUC4 in pancreatic adenocarcinoma cell lines. (A) A total of 10 mg protein from cell extracts
were resolved by electrophoresis on a 2% SDS-agarose gel containing Tris – glycine (pH 8.8) buffer, transferred to PVDF membrane and incubated with antiMUC4 monoclonal antibody. The membrane was then probed with HRPO-labelled goat anti-mouse Ig. Immunoblot of actin, obtained from 10% SDSpolyacrylamide gel, was used as an internal control. (B) Confocal photomicrograph demonstrating expression pattern of MUC4 in methanol-fixed human
pancreatic tumor cells. The cells were grown at low density on coverslips for 24 h, and the acetone/methanol (1 : 1)-fixed cells were labelled using a FITCconjugated anti-MUC4 monoclonal antibody and counterstained by propidium iodide. Magnification,  630.

experiment was performed. The mini-MUC4 overexpressing cells
were seeded in six-well plates in triplicate and counted for 5 days.
The experiment was carried out for both Panc1 and MiaPaCa
transfected with mini-MUC4, in medium containing high (10%)
and low (1%) serum. No significant difference was observed for the
mini-MUC4-transfected Panc1 and MiaPaca cells grown in 10%
serum when compared to the control (Figure 3A). All cell lines
presented similar population doubling time. However, when the
cells were maintained in medium containing low serum, the miniMUC4-transfected Panc1 cells grew much faster, with a population
doubling time of 18.47 h as compared to 33 and 32.6 h for the
parental and mock cells, respectively (Figure 3B). The difference
was statistically significant with a Po0.022. The results obtained
for the MiaPaCa lineage was comparable; however, we were unable
to calculate the population doubling time for the parental or mock
& 2007 Cancer Research UK

cells, the majority of the cells did not survive for more than 5 days
in low serum (Figure 3B). After 5 days of growth in low serum, the
difference in cell number between the control and the mini-MUC4positive MiaPaCa cells were statistically significant with a
Po0.013.

MUC4 induced mitochondrial mass increase in pancreatic
cancer cells
The phenotypic modifications due to mini-MUC4 overexpression
were investigated by electron microscopy studies. The studies were
performed for both Panc1 and MiaPaCa cells transfected with
mini-MUC4 and control cells. The cells transfected for mini-MUC4
expression presented a Golgi system well developed with
accumulation of numerous vacuoles, sign of active biosynthesis
British Journal of Cancer (2007) 97(3), 345 – 357
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Figure 3 Growth kinetic patterns of the parental, vector control, and mini-MUC4-expressing cells. The cells were plated at a density of 104 per well into
six-well plates, grown for 6 days, and counted each day after seeding. The graph presents the result obtained in terms of the number of cells as a function of
increasing duration. (A) The cells were maintained in medium containing 10% serum. (B) The cells were maintained in medium containing 1% serum.

(Figure 4, right panel). In addition, the mini-MUC4-transfected
cells showed an increased number of large, elongated, and
centrally narrow mitochondria (Figure 4, right panel). The parental
cells and the cells transfected with vector alone had mitochondria
of normal size and shape (oval and round). The presence of
elongated and centrally narrow mitochondria indicates increased
mitochondrial divisions in mini-MUC4-transfected cells. The
number of mitochondria examined in five fields was counted for
Panc1 and Panc1 mini-MUC4 cells. Panc1 cells presented 28714
mitochondria per field, whereas Panc1 mini-MUC4 presented
7075 mitochondria (Po0.005). The mitochondrial abnormalities
observed in mini-MUC4-transfected cells by electron microscopic
studies were further evaluated using specific fluorescent mitochondrial probes. The fluorescent dye, NAO, which specifically
binds to cardiolipin at the inner mitochondrial membrane
independent of the membrane potential, was utilised to measure
the changes in mitochondrial mass. To monitor the effect of miniMUC4 overexpression on mitochondrial mass, two independent
clones showing different expression levels of mini-MUC4 in Panc1
cells were investigated. The NAO uptake was compared in miniMUC4-transfected and control cell lines. Figure 5 presents the
NAO intensity measured for each cell line, the relative NAO
intensity calculated for 20 000 randomly selected cells within each
cell population indicated below. As shown in a table in Figure 5,
the relative NAO intensity of the MUC4-transfected cells (with a
mean of 88.05 and 103.43 for the cell lines expressing low and high
levels of transfected mini-MUC4, respectively) was higher than the
control cell lines (with a mean of 67.3 and 63.25, respectively, for
the parental cells and the cells transfected with vector control).
Hence, there was a progressive increase in mean NAO fluorescence
British Journal of Cancer (2007) 97(3), 345 – 357

of mini-MUC4-transfected Panc1 cells with increasing levels of
MUC4 expression, which was also consistent with the increased
number of mitochondria observed by electron microscopy. These
results indicate a potential correlation between NAO uptake and
MUC4 expression. The cell-cycle analysis, investigated by propidium iodide staining, showed no difference in the relative number
of cells arrested at the late G1, G0/G1, and G2/M phases. The MUC4dependent increase in mitochondrial mass appeared to be
independent of the cell cycle. The difference in mitochondrial
membrane potential between the mini-MUC4-transfected and
control cells was analysed by utilising a lipophilic cation JC-I
(5,50 ,6,60 -tetrachloro 1,10 ,3,3-tetraethylbenzimidazolcarbocyanine
iodide dye). This mitochondrial dye exists as a monomer in
solution and the monomers aggregate as a function of the
mitochondrial membrane potential. The JC-I monomer fluoresces
at 530710 nm and the JC-I aggregate fluoresces at 590717 nm.
The ratio of aggregate fluorescence to monomer fluorescence is an
indication of mitochondrial membrane potential. The DCm was
measured in mini-MUC4-expressing Panc1 cells and control cells
by a ratio of 527/590 nm (data not shown). No significant
difference was observed in the mitochondrial membrane potential
using the JC-I dye, showing that the increase in mitochondrial
mass was not associated with an increase in apoptosis. The
apoptosis status of the control and mini-MUC4-corrected cells was
confirmed by annexin V staining by flow cytometry and poly
(ADP-ribose) polymerase (PARP) degradation by western blot
(Figure 6), but no significant difference in apoptosis was observed.
However, the percentage necrotic cells was significantly increased
(Po0.05) in Panc1 cells overexpressing mini-MUC4 as compared
with control cells.
& 2007 Cancer Research UK
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Figure 4 Electronmicroscopy. Cells, cultured at 70% confluence, were fixed with 2.5% glutaraldehyde in 1 M Sorenson’s phosphate buffer. The cell pellet
was then subjected to overnight infiltration in Dureapam Acm. Epoxy Resin (Electron Microscopy Sciences), flat embedding, and polymerisation at 551C for
48 h. Embedded cells were mounted on resin stubs and sectioned at 90 nm with an Ultracut E ultramicrotome. Sections were viewed and photographed
with a Zeiss 600 EM10A TEM at 60 Kv. The pictures presented are representative for the experiment. Twenty cells for each cell line were observed in two
independent experiments. The black arrows indicate dividing mitochondria in the MiaPaCa cell line transfected with mini-MUC4 construct and the red
arrows indicate the golgi complex.

The cDNA microarray hybridisation and analysis
The variations in gene expression between the mini-MUC4expressing Panc1 cells and mock-transfected cells were analysed
by performing cDNA microarray hybridisation. A scattered pattern
of expression was obtained when comparing the genes expressed
in mini-MUC4-expressing Panc1 cells (presenting the highest
levels of expression for mini-MUC4) vs the mock cell line. Among
& 2007 Cancer Research UK

all the genes, 54 genes showed at least twofold change in
expression after normalisation. The 33 genes which were overexpressed at least twofold in mini-MUC4-expressing Panc1 cells
are listed in Table 1 and the 21 genes which showed at least twofold
decrease in expression are listed in Table 2. Among the 33 genes
overexpressed in mini-MUC4-expressing cells, four coded for
proteins, which are required for mitochondrial functions. These
genes are the succinyl CoA synthetase, the succinyl CoA:3-oxoacid
British Journal of Cancer (2007) 97(3), 345 – 357
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Figure 5 Determination of the mitochondrial mass. (A) The fluorescent dye NAO was used to monitor the mitochondrial mass in low MUC4-expressing
(thin black curve) and high MUC4-expressing (thick black curve) Panc1 cell lines. These cell lines were compared with the parental Panc1 cells (thin grey
curve) and the mock cells (discontinuous curve). The relative NAO intensity of the mini-MUC4-transfected cells (with a mean of 88.05 and 103.43 for the
mini-MUC4 low and high expressing cell lines respectively) was higher than the control cell lines (with a mean of 67.3 and 63.25 for the parental and mock
cell lines, respectively). (B) Western blot analysis of the low and high mini-MUC4 expressing cells compared with both Panc1 and Panc1 pSecTag control
cell. As positive control, the HPAF/CD18 cells were used. (C) The NAO relative intensity was plotted depending on the mini-MUC4 expression. MiniMUC4 expression was normalised with b-actin. One-hundred counts for MUC4 expression were empirically attributed to the mini-MUC4-expressing cells.

transferase, the glycerol-3-phosphate dehydrogenase 2 (GPD2),
and the isovaleryl CoA dehydrogenase (IVD). Five other genes
were found to be overexpressed with a level close to the twofold
cutoff: the alcohol dehydrogenase (ADH), the ATP-binding
cassette transporter (ABC2), the thioredoxin reductase (TrxB2),
the outer mitochondrial membrane 34 kDa translocase (TOM34),
and the pyruvate kinase. Altogether, nine genes coded for proteins
located and functionally active within the mitochondria. The
overexpression of mitochondrial genes in mini-MUC4-transfected
Panc1 was consistent with the increased number of mitochondria
observed by electron microscopic studies. This indicated increased
energy generating ability of MUC4-expressing cells that might
enhance the tumorigenicity and metastatic potential of pancreatic
adenocarcinoma cells.

to the lower surface of the porous membrane under chemoattractive stimulus of FBS in the lower chamber was approximately
twofold greater in both mini-MUC4-expressing pancreatic cancer
cells in comparison with control transfected cells (Figure 7A). An
in vitro cell invasion assay was performed based on the principle of
the Boyden chamber assay. The Matrigel matrix served as a
reconstituted basement membrane in vitro. The cells migrating
through the Matrigel matrix under chemoattractive stimulus of
FBS in the lower chamber were counted and the result is presented
in Figure 7B. The mini-MUC4 overexpressing cells showed
significantly enhanced invasiveness (B1.5-fold) as compared with
the control cells (Po0.05). These data indicated that the enhanced
expression of MUC4 in pancreatic cancer cells is associated with
increased invasiveness.

MUC4 overexpression enhances cell motility and
invasiveness of pancreatic cancer cells

Overexpression of mini-MUC4 results in an increase in
tumorigenicity of the Panc1 and MiaPaCa cells

To examine the effect of mini-MUC4 expression on cancer cell
properties, a motility and invasion assay was performed. A cell
motility assay was performed by utilising uncoated porous
membranes of 8.0 mm pore diameter. The number of cells migrated

To determine the effect of MUC4 expression on tumorigenicity and
metastatic potential of pancreatic adenocarcinoma cells, tumorigenicity, and metastatic index were determined by transplanting
the tumour cells orthotopically in the pancreas of the nude mice.
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Figure 6 Analysis of the apoptotic and necrotic indices in mini-MUC4-overexpressing cells vs control cells. Panc1, either overexpressing mini-MUC4 or
transfected with vector only, were serum starved 16 h to induce apoptosis. The percentage of cells undergoing apoptosis and necrosis was measured by
annexin V and propidium iodide staining, respectively, followed by fluorescence-activated cell sorting analysis. (A) The bars represent the mean percentage
of the apoptotic and necrotic cells (n ¼ 3, *Po0.05). (B) Western blot analysis to show the PARP activity in Panc1, Panc1-pSecTag C, and Panc1-miniMUC4 cell lysates. A total of 30 mg protein from cell extracts were resolved by electrophoresis on a 10% SDS-polyacrylamide gel, transferred to PVDF
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control.

We have previously reported that the inhibition of MUC4
expression by antisense technique in the well-differentiated cancer
cell line, CD18/HPAF, reduced tumorigenicity, and metastasis in
vivo (Singh et al, 2004). To confirm that mini-MUC4 plays a
similar role in tumour development compared with the wild-type
MUC4, we examined the changes in the tumorigenicity and
metastatic potential of mini-MUC4-transfected Panc1 and MiaPaCa cells in vivo. Two million cells were implanted into the pancreas
and tumour formation was checked twice a week in the first 2
weeks and daily thereafter. Primary tumours were resected, and
data were recorded for tumour weight and volume (Table 3).
Seventy-five percent and 64% of the mice injected with the Panc1
parental or vector-transfected control cells, respectively, developed
primary tumours as compared with 100% for the cells expressing
mini-MUC4 (Table 3). However, this difference in the percentage
of animals harbouring tumours was not statistically significant.
Among animals with tumour present, the tumour weight was
significantly higher for the Panc1 cells expressing mini-MUC4 as
compared with the parental cells (Po0.01) and the vectortransfected cells (Po0.01). Similar results were obtained for the
tumour volume for Panc1 cells expressing mini-MUC4 vs Panc1
parental (Po0.01) and for Panc1 transfected with mini-MUC4 vs
vector-transfected cells (Po0.01). No statistically significant
difference was observed for the metastasis frequency. Only lymph
node involvement was detected by macroscopic examination of the
mice in 27% of the cases for the Panc1 cells expressing mini-MUC4
and 17 – 18% for the control cells. The number of macroscopic
metastases per mice was comparable for all the three cell lines
investigated. The results for the mini-MUC4-expressing MiaPaCa
cells are not presented here, but their implantation in mice
provided similar results as for the mini-MUC4-expressing Panc1
cells.
& 2007 Cancer Research UK

DISCUSSION
Mucins are characterised by the presence of mucin domain, which
is the largest domain and rich in serine, threonine, and proline
residues. It is composed of highly glycosylated repetitive units that
confer an extended conformation to the mucins due to the
presence of multiple proline residues. For instance, the largest
MUC4 allele identified, so far, is transcribed into RNA of 26.5 kb
(Nollet et al, 1998). Within this 26.5 kb, 19 kb is composed of a
48 bp motif repeated up to 400 times, and this RNA encodes an
estimated 2.12 mm-long protein. Although the structural organisation of most of the human mucins has been elucidated, their
functions in human are still not well understood. This lack of
knowledge is partly due to the complexity of their transcripts and
the large size of the encoded proteins. One of the classic techniques
to investigate the protein functions consists of overexpression of
the corresponding gene in a cell line model and to study the
phenotypic changes. The large size of MUC4 RNA, however, makes
this technique very difficult to perform. In this study, a miniMUC4 construct was generated, containing the complete 50 - and
30 -unique sequences of MUC4, but with 1.8 kb of its repetitive
domain instead of the original 7 – 19 kb. The MUC4 minigene is
8781 bp long and encodes an estimated 320 kDa protein. It
represents one-third of the estimated size of the largest MUC4
allele and two-third of the smallest MUC4 allele reported. MiniMUC4 is almost equal in size to its rat homologue, SMC/Muc4
(Carraway et al, 2000).
In our previous studies, inhibition of MUC4 expression reduced
in vitro growth of pancreatic cancer cells (Singh et al, 2004).
Another study performed on rat Muc4/SMC also proves the
involvement of MUC4 mucin in growth advantage to cancer cells
(Komatsu et al, 2001). In this study, the ectopic expression of
British Journal of Cancer (2007) 97(3), 345 – 357
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Table 1 Genes overexpressed in the mini-MUC4-transfected cells in
comparison with the control cells

Table 2 Genes downregulated in the mini-MUC4-transfected cells in
comparison with the control cells

Accession
number
Name

Fold
upregulated

Accession
number

Name

4.08
4.01
3.61
3.57
3.54
3.50

H63077
AA478589
AA167222
H60549
T94626
H77766
R43544
H71847
R09561
AA489569
AA284668
AA132090
AA412053
H72722
T96083
R05336
T72877
AA598478
N71159
R94153
H16637

Annexin I (lipocortin I)
Apolipoprotein E
Collagen type XIV
Ribosomal protein S26
Fibrinogen g-A chain precursor
Metallothionein
Ribosomal protein L32
Flavin-containing monooxygenase 2
Decay accelerating factor for complement
Mesothelial keratin K7 (type II)
Urokinase-type plasminogen activator
CD53 antigen
CD9 antigen
Metallothionein I-B gene
Low-Mr GTP-binding protein (RAB31)
b-1,4 N-acetylgalactosaminyltransferase
Interleukin-1 receptor antagonist
Complement component 7
Metastasis-associated mta1
Inositol 1,4,5-trisphosphate 3-kinase B
Vascular cell adhesion molecule 1

W38923
N90368
R25074
W60015
N72452
H11692
T51895
R59579
AA490680
H07991
H29256
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AA410680
AA453105
AA037014
H11792
R22274
N80617
H54686
AA491302
T64134
AA457051
R40897
AA489743
AA482128
AA169176
N79051
AA464149
AA489714
H37761
AA455712
W23757
AA521453
R19878

Transmembrane receptor (ror2)
Succinyl-CoA synthetase
Transmembrane 4 superfamily protein (SAS)
Translation initiation factor eIF-2a
RAD52 (Sachharomyces cerevisiae) homolog
Neuron-specific vesicle coat protein and cerebellar
degeneration antigen (b-NAP)
Hepatoma transmembrane kinase
Prostaglandin D2 synthase
Transcobalamin II
Vascular endothelial growth factor related protein
VRP
Neuronal DHP-sensitive, voltage-dependent calcium
channel a-1D subunit
Tropomodulin
Histone 2A-like protein (H2A/l)
Prostaglandin transporter hPGT
Putative splice factor transformer2-b
Phosphoethanolamine cytidylyltransferase
Multidrug resistance-associated protein homolog
(MRP5)
Mitogen-responsive phosphoprotein (DOC-2)
Islet cell autoantigen 1 (69 kDa)
Monocyte chemoattractant protein-4 precursor
(MCP-4)
Lymphoid-restricted membrane protein (Jaw1)
Succinyl CoA:3-oxoacid CoA transferase precursor
(OXCT)
Interferon-inducible 56-kDa protein l
Protein-tyrosine kinase tyk2 (non-receptor)
Glycerol-3-phosphate dehydrogenase 2
(mitochondrial)
Transmembrane tyrosine-specific protein kinase
ROS1
Isovaleryl coenzyme A dehydrogenase
Homosapiens mRNA for ZYG homologue
Mitogen induced nuclear orphan receptor (MINOR)
Kruppel-related zinc finger protein (ZNF184)
Keratin 13
Human flightless-I
Reelin (RELN)

3.44
3.30
3.19
2.99
2.97
2.88
2.81
2.75
2.70
2.69
2.45

5.33
4.64
2.91
2.89
2.74
2.72
2.59
2.58
2.52
2.51
2.50
2.43
2.36
2.26
2.26
2.21
2.14
2.13
2.11
2.03
1.84

2.38
2.30
2.26
2.26
2.19
2.16
2.10
2.09
2.08
2.08
2.08
2.06
2.03
2.01
2.01
2.00

mini-MUC4 showed an increased in vitro growth. Our in vivo
studies also indicated that mini-MUC4 expression is associated
with increased tumorigenicity of human pancreatic cancer cells.
To evaluate the role of MUC4 in cell behavioral properties, we
performed cell motility and invasion assays. The mini-MUC4
containing cells were more motile on uncoated 8 mm pore
membrane. A decrease in motility was observed when MUC4 was
downregulated, using an antisense technology in CD18/HPAF cells,
in comparison with mock-transfected cells. Furthermore, the miniMUC4-transfected cells also presented an increased capacity to
invade through the Matrigel-coated membrane. Hence, the
expression of mini-MUC4 is associated with more aggressive
phenotype. This property further implies that mini-MUC4 has the
similar effects as wild-type MUC4 and will be valuable tool to
dissect further the MUC4-mediated functions.
Our results present that MUC4 provides growth advantage to the
cells and is associated with an increase in mitochondrial mass,
without changing the polarity of the mitochondrial membranes.
The mitochondrial mass varies with the type of the cells and
tissues, and is changed during cell differentiation, hormone
treatment, and exercise (Robin and Wong, 1988; Renis et al,
1989; Shay et al, 1990). An increase in mitochondrial mass is
known to be related to drug treatment affecting the cell cycle
British Journal of Cancer (2007) 97(3), 345 – 357
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(Pagliacci et al, 1993; Mancini et al, 1997). For instance, oxidative
stress induced by H2O2 leads to an increase in mitochondrial mass
in fibroblast. An increase in mitochondria can occur even in the
absence of nuclear DNA replication (Sazer and Sherwood, 1990).
Apart from that, mitochondria and mitochondrial DNA replication
are also observed in the G2/M cell-cycle arrest. The increase in
number of mitochondria occurs during cellular differentiation.
The progress of differentiation in a normal cell depends on the
increase in the ratio between the mitochondrial differentiationpromoting activity and decrease in nuclear-preventing activity
(von Wangenheim and Peterson, 1998). During the differentiation
process, the mitochondrial growth occurs at a rate that doubles its
amount after each cycle. The high cytoplasmic to nuclear ratio
determines the cells to differentiate, followed by apoptosis. The
relationship between mitochondria and apoptosis is well established (Green and Reed, 1998). The mitochondria is known to
regulate apoptosis by releasing the apoptogenic factors such as
cytochrome c from their intermembrane space into the cytoplasm
(Kluck et al, 1997). The release of cytochrome c initiates caspase
activation (Liu et al, 1996). An increase in mitochondria mass is,
therefore, considered as one of the final steps during differentiation, just prior cell death by apoptosis (von Wangenheim and
Peterson, 1998). The transfection of mini-MUC4 in Panc1 cell line
(a poorly differentiated cell line) increased the mitochondrial mass
but was not accompanied by an increase in the apoptotic index and
change in the polarisation state of the mitochondrial membrane. A
similar observation has been reported in breast cancer, where
resistance to tamoxifen-induced apoptosis was correlated with an
increase in mitochondrial mass (Dietze et al, 2001). In this paper,
we showed that MUC4 induces an increase in mitochondrial mass
without changing the apoptotic index. However, in our MUC4
knockdown cell line model, we showed that endogenous overexpression of MUC4 is preventing apoptosis of the CD18/HPAF
pancreatic cancer cells after 48 – 72 h serum starvation (Chaturvedi
et al, 2007). The lack of detection of any significant change in
apoptosis and PARP activity in mini-MUC4-transfected cells might
be due to the fact that apoptosis was induced by serum starving the
cells for less than 24 h. The shorter duration of serum starvation
was applied owing to the reason that Panc1 cells and their
derivatives cannot survive for more than 24 h in serum-free media.
However, we found a significant upregulation in necrosis of Panc1
& 2007 Cancer Research UK
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Figure 7 Expression of mini-MUC4 increases the motility and invasiveness of pancreatic cancer cells. (A) Cells were plated onto non-coated membranes
for motility assays. The cells were incubated for 24 h, and those that did not migrate through the pores in the membrane were removed by scraping the
membrane with a cotton swab and the remaining cells were stained. Cells that migrated through the pores were counted, and representative fields were
photographed under bright field microscopy. Quantitation of cells invaded through the membrane in the above experiments is presented as a bar diagram.
The mini-MUC4-expressing cells showed significant increase in cell motility as compared to control cells (*Po0.001). (B) Matrigel invasion assay to measure
the invasive potential of mini-MUC4-expressing cells. The invasion of mini-MUC4-expressing and control cells through extracellular matrix was investigated
using Matrigel invasion chambers. The 10% FBS was used as a chemoattractant in lower chambers. Cells migrated through the Matrigel matrix were counted,
and representative fields were photographed under bright field microscopy. Quantitation of cells invaded through the Matrigel matrix in the above
experiments is presented as a bar diagram. The mini-MUC4-expressing cells showed higher invasive index than the control cells (*Po0.05).

Table 3 Growth of pancreatic tumours developed by orthotopic implantation of Panc1 control (parental and vector-transfected) and mini-MUC4expressing cells in immunodeficient mice
Cell line

Mice with
tumour (%)

Median tumour
weight (mg)

Median tumour
volume (mm3)

Mice with metastases
(%)

Panc1 mini-MUC4
Panc1
Panc1 pSecTag C

11/11 (100%)
9/12 (75%)
7/11 (64%)

10507150a
235735
145720

770755a
2875
2072

3/11 (27%)
2/12 (17%)
2/11 (18%)

Mice were injected orthotopically with 2  106 cells from Panc1, vector transfected and mini-MUC4-expressing cell lines in beige nude mice. Mice were killed at day 60 postinjection and tumours were resected, weighed, and their dimensions were measured. The mini-MUC4-expressing cells showed a significant increase in tumour weight, tumour
volume but no significant difference in metastasis was observed. aPo0.0001 compared with Panc1 pSecTag C.
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cells transfected with vector in comparison with mini-MUC4transfected cells. Necrosis is a way of cell death in the absence of
significant pools of cellular ATP. Despite having apoptotic signals,
cells would still undergo necrosis if the ATP levels are low.
Presence of mini-MUC4 by itself might be providing survival
signals and preventing the apoptosis; however, due to lack of
survival signals in the absence of mini-MUC4 and due to reduced
levels of ATP in the vector containing cells, these cells might
undergo necrosis (Bernardi et al, 1999; Denecker et al, 2001). The
mechanism and the pathways involved in this phenomenon still
need to be determined. Thus, results suggest that MUC4, by
increasing mitochondrial mass, most probably contributes to the
redox status of the cells, which in turn provides the cancer cells
with a survival advantage in pre-angiogenesis, leading to increased
tumour progression. This advantage was observed when the cells
were grown in medium containing low serum concentration.
Control cells were dying over time, whereas the MUC4-expressing
cells survived and expanded.
Microarray analysis performed using the mini-MUC4 cellular
model revealed overexpression of numerous genes coding for
mitochondrial proteins in mini-MUC4-expressing cells (Table 1).
These upregulated genes code for various enzymes that regulate
different mitochondrial functions, such as citric acid cycle,
ketoacidosis, glycolysis, amino acid, and lipid metabolism. None
of the deregulated genes code for proteins implicated in other
mitochondrial functions, such as apoptosis. Therefore, it appears
that the mini-MUC4-mediated increase in mitochondrial mass is
directly associated with an increase in metabolic activity.
Mitochondrial mass regulation is a key point of numerous
physiologic processes, including embryonic development, fat
metabolism, and ageing. Our results present MUC4 as a partner
in the regulation of these vital physiological steps. MUC4, at the
surface of the epithelial cells, might act as an active sensor for a
differentiation pathway. Some of the genes downregulated in miniMUC4-overexpressing cells were annexin I, apolipoprotein,
collagen type XIV, CD53, CD9 antigen, metastasis associated
(mta 1) and vascular cell adhesion molecule 1 (Table 2). The mta 1

and vascular cell adhesion molecule are known to be involved in
the metastasis processes (Langley et al, 2001; Hofer et al, 2004).
The nonsignificant changes in metastasis may be explained in part
by downregulation of these genes in mini-MUC4-transfected cells.
One of the hypotheses that would need to be further investigated
is the resistance to hypoxia-induced apoptosis driven by the
increase in mitochondrial mass after mini-MUC4 overexpression.
Cancer cells overexpressing MUC4 might use this strategy to
survive and establish themselves before angiogenesis takes place.
Some evidence is provided by the fact that only tumorigenicity was
increased by mini-MUC4 overexpression and not the metastatic
index. This observation suggests that an increase in tumorigenicity
is associated to the unique sequence of MUC4 (MUC4b for
instance) and the increase in metastatic index is related to the size
of the large repetitive domain present in MUC4a.
In conclusion, our data provide evidence supporting the role of
MUC4 mucin in the progression of pancreatic cancer. We
demonstrate that MUC4 enhances the growth, motility, and
invasive properties of pancreatic cancer cells in vitro. Overexpression of MUC4 mucin also induces cellular changes and
tumour progression of pancreatic cancer cells. Hence, MUC4 can
be a useful target in the development of novel therapeutic
strategies for the treatment of pancreatic cancer.
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